Synonymous ADAMTS13 variants impact molecular characteristics and contribute to variability in active protein abundance

Blood Adv. 2022 Sep 27;6(18):5364-5378. doi: 10.1182/bloodadvances.2022007065.

Abstract

The effects of synonymous single nucleotide variants (sSNVs) are often neglected because they do not alter protein primary structure. Nevertheless, there is growing evidence that synonymous variations may affect messenger RNA (mRNA) expression and protein conformation and activity, which may lead to protein deficiency and disease manifestations. Because there are >21 million possible sSNVs affecting the human genome, it is not feasible to experimentally validate the effect of each sSNV. Here, we report a comprehensive series of in silico analyses assessing sSNV impact on a specific gene. ADAMTS13 was chosen as a model for its large size, many previously reported sSNVs, and associated coagulopathy thrombotic thrombocytopenic purpura. Using various prediction tools of biomolecular characteristics, we evaluated all ADAMTS13 sSNVs registered in the National Center for Biotechnology Information database of single nucleotide polymorphisms, including 357 neutral sSNVs and 19 sSNVs identified in patients with thrombotic thrombocytopenic purpura. We showed that some sSNVs change mRNA-folding energy/stability, disrupt mRNA splicing, disturb microRNA-binding sites, and alter synonymous codon or codon pair usage. Our findings highlight the importance of considering sSNVs when assessing the complex effects of ADAMTS13 alleles, and our approach provides a generalizable framework to characterize sSNV impact in other genes and diseases.

MeSH terms

  • ADAMTS13 Protein / genetics
  • Codon
  • Humans
  • MicroRNAs*
  • Nucleotides
  • Purpura, Thrombotic Thrombocytopenic* / genetics
  • RNA, Messenger / genetics

Substances

  • Codon
  • MicroRNAs
  • Nucleotides
  • RNA, Messenger
  • ADAMTS13 Protein
  • ADAMTS13 protein, human